FierceBiotech 2026年4月1日 Valneva CEO on Pfizer-partnered Lyme vaccine: Why a phase 3 miss doesn’t tell the whole story
FierceBiotech 2026年4月1日 ‘There isn't as much meat left to cut’: Biopharma layoffs maintain slowdown in Q1
FierceBiotech 2026年4月1日 Oric chases Pfizer into phase 3 hailing prostate cancer edge, but investors send stock down
FierceBiotech 2026年4月1日 KBP hopes to revive troubled heart drug at center of deal fraud dispute with Novo Nordisk
FierceBiotech 2026年3月31日 Iterum initiates wind-down after failure to offload antibiotic with sluggish sales
FierceBiotech 2026年3月31日 Lilly pays $6.3B upfront for sleep disorder-focused Centessa in latest neuroscience play
FierceBiotech 2026年3月31日 Obesity biotech Ambrosia scores $100M series B to take next-gen oral GLP-1 into the clinic
FierceBiotech 2026年3月31日 AstraZeneca’s Strensiq successor misses phase 3 rare disease goal, denting market expansion plan
FierceBiotech 2026年3月31日 Lipella files for bankruptcy, ending dream of developing mouth inflammation drug
FierceBiotech 2026年3月30日 Astellas axes early Sjögren’s trial in latest setback for autoimmune disease community